Ursodeoxycholic acid for treatment of cholestasis in patients with hepatic amyloidosis by Faust Dominik et al.
Strana 482 VOJNOSANITETSKI PREGLED Volumen 66, Broj 6
Correspondence to: Dominik Faust, Asklepios Hospital, Department of Medicine, Bad Muender, Germany.
E-mail: innere2.longen@asklepios.com
CASE REPORTS UDC: 616.36-008.6-08
Ursodeoxycholic acid for treatment of cholestasis in patients with
hepatic amyloidosis
Ursodeoksiholna kiselina za lečenje holestaze kod bolesnika
sa amiloidozom jetre
Dominik Faust*, Bora Akoglu
†, Gordana Ristic
†, Vladan Milovic
†
Asklepios Hospital, *Department of Medicine, Langen, Germany; MediClin Deister
Weser Hospital, 
†Department of Gastroenterology and Oncology, Bad Muender, Germany
Abstract
Background. Amyloidosis represents a group of different dis-
eases characterized by extracellular accumulation of pathologic
fibrillar proteins in various tissues and organs. Severe amyloid
deposition in the liver parenchyma has extrahepatic involve-
ment predominantly in the kidney or heart. We evaluated the
effect of ursodeoxycholic acid, in four patients with severe he-
patic amyloidosis of different etiologies, who presented with
increased alkaline phosphatase and γ-glutamyl transferase. Case
report. The study included four patients who presented with
amyloidosis-associated intrahepatic cholestasis. Three of them
had renal amyloidosis which developed 1–3 years before chole-
stasis occurred, the remaining one having intrahepatic cholesta-
sis as the primary sign of the disease. Amyloidosis was identi-
fied from liver biopsies in all patients by its specific binding to
Congo red and green birefringence in polarized light. The bio-
chemical nature and the class of amyloid deposits were identi-
fied immunohistochemically. In addition to their regular treat-
ment, the patients received 750 mg ursodeoxycholic acid per
day. After 2–4 weeks all patients had a significant decrease of
serum alkaline phosphatase and γ-glutamyl transferase, and
their general status significantly improved. Conclusion.
Treatment with ursodeoxycholic acid may be beneficial in pa-
tients with hepatic amyloidosis, and do extend indications for
the use of ursodeoxycholic acid in amyloidotic cholestatic liver
disease.
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Apstrakt
Uvod. Amiloidoza predstavlja grupu različitih oboljenja
koju karakteriše vanćelijsko nakupljanje patoloških fibrilnih
proteina u različtim tkivima i organima. Značajno nakuplja-
nje depozita u parenhimu jetre prati ekstrahepatična zahva-
ćenost pre svega bubrega ili srca. Ispitivan je efekat ursode-
oksiholne kiseline kod četiri bolesnika sa amiloidozom jetre
različite etiologije koji su primljeni zbog povišenja alkalne
fosfataze i gama glutamil transferaze. Prikaz bolesnika.
Opisali smo četiri bolesnika sa intrahepatičkom holestazom
udruženom sa amiloidozom. Tri od četiri bolesnika imala su
amioloidozu bubrega koja se razvila 1–3 godine pre pojave
holestaze, a jedan bolesnik holestazu kao prvi znak bolesti.
Amiloidoza je dokazana iz biopsija jetre nakon specifičnog
bojenja Kongo crvenim. Biološka priroda i klasa amiloida
ispitana je imunohistohemijski. Zajedno sa njihovom uobi-
čajenom terapijom, bolesnici su lečeni ursodeoksiholnom
kiselinom, 750 mg dnevno. Posle 2–4 nedelje kod svih bole-
snika dokazan je značajni pad alkalne fosfataze i gama glu-
tamil transferaze, i njihovo opšte stanje značajno se popra-
vilo. Zaključak. Terapija ursodeoksiholnom kiselinom us-
pešna je kod bolesnika sa amiloidozom jetre, čime se proši-
ruje indikacija za davanje ursodeoksiholne kiseline kod bole-
snika sa holestazom koja nastaje kao posledica jetrene ami-
loidoze.
Ključne reči:
amiloidoza; holestaza; biopsija; imunohistohemija;
dezoksiholna kiselina.
Introduction
Amyloidosis represents a group of different diseases
characterized by extracellular accumulation of pathologic
fibrillar proteins (called amyloid on the basis of special
tinctorial and optical properties) in various tissues and or-
gans. Systemic amyloidosis may present as predominantly
renal disease. Severe amyloid deposition in the liver paren-
chyma has been described as much less common than renal
amyloidosis, occurring in approximately 5% of patients with
simultaneous renal involvement 
1. In turn, the majority of
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involvement predominantly in the kidney (47%) or heart
(42%) 
2. Regarding poor median survival rate of patients
with severe hepatic amyloidosis and the failure of existing
treatment options to improve survival and relieve cholestasis,
novel therapeutical approaches are obviously needed.
When used to dissolve gallstones in patients with
chronic active hepatitis, the dihydroxylated bile acid, urso-
deoxycholic acid, improved both serum transaminases and
cholestasis-indicating enzymes 
3. Ursodeoxycholic acid has
also been used in patients with cystic fibrosis, and is the
treatment of choice in primary biliary cirrhosis 
4–6. In the
present study, we administered ursodeoxycholic acid to four
patients with cholestasis due to amyloidosis with hepatic in-
volvement. Rapid improvement of cholestasis after the
treatment was initiated, recurrence of cholestasis after urso-
deoxycholic acid was temporarily discontinued and repeated
improvement after the drug was reintroduced, suggest that
ursodeoxycholic acid may be an efficient therapy in patients
with cholestasis due to hepatic amyloidosis.
Case report
The study included four patients who presented with
amyloidosis-associated intrahepatic cholestasis (Table 1).
Three of the four patients had renal amyloidosis which de-
veloped 1–3 years before cholestasis occurred. The patient
1 was a 44-year-old Caucasian female with immunoglobu-
lin-light-chain-λ-related (ALλ) amyloidosis, while two
males, patient 2 (65-year-old Caucasian) and patient 3 (40-
year-old African), had amyloid protein A (AA) amyloido-
sis. In contrast, the patient 4 (70-years-old Caucasian male)
had no overt renal amyloidosis, and intrahepatic cholestasis
was the primary sign of the disease. Familial Mediterranean
fever was the cause of amyloidosis in one of two patients
with AA amyloidosis (patient 2). In patients 1, 3 and 4 no
cause could initially be identified, and, in particular,
chronic inflammatory bowel disease and Mediterranean fe-
ver were ruled out.
Two out of four patients (patients 1 and 2) complained
to pruritus as the only cholestasis-related symptom. Pa-
tients 1 and 2 were in the end-stage renal disease and un-
dergoing hemodialysis. They were both receiving ACE in-
hibitors and calcium antagonists to treat renal hypertension.
The patient 3 had moderately impaired renal function with-
out indications for hemodialysis, and was receiving no
medication. The patient 4 had coronary heart disease and,
as regular therapy, was receiving acetylsalicylic acid and
metoprolol daily.
Laboratory data are summarized in Tables 1 and 2. Ex-
trahepatic cholestasis was excluded in all patients by ultra-
sound. Magnetic resonance cholangiopancreatography was
additionally done in Patient 3, confirming normal morphol-
ogy of intra- and extrahepatic bile ducts.
Liver biopsies were performed in all patients and evalu-
ated separately by two pathologists. They revealed severe
capillary amyloid deposits along the sinusoids and in the
walls of hepatic arteries, and were diagnostic for amyloido-
sis, according to the criteria described before 
7. Amyloid was
identified at light microscopy by its specific binding to
Congo red and its green birefringence in polarized light. The
biochemical nature and the class of amyloid deposits were
identified immunohistochemically, as previously described 
8.
Table 1
Survey of blood cell count, clinical chemistry and clotting tests before and after four weeks of treatment
with ursodeoxycholic acid (750 mg per day)
Patient 1 Patient 2 Patient 3 Patient 4
Week 0 Week 4 Week 0 Week 4 Week 0 Week 4 Week 0 Week 4 Normal range
Hemoglobin, (g/dL) 10.2 10.6 11.5 11.3 13.4 13.8 13.8 12.1 12.5–17.5
Leucocytes, (nL) 8.3 9.2 7.6 10.8 6.45 5.60 8.78 8.11 3.5–9.8
Sodium, (mmoL/L) 141 140 142 137 136 141 138 143 135–155
Creatinine, (mg/dL) 5.9 8.0 6.8 6.8 2.9 2.7 0.80 1.1 < 1.44
Cholesterol, (mg/dL) 283 256 166 236 172 185 232 211 < 200
Albumin, (g/dL) 4.7 3.7 3.8 3.8 3.5 3.7 4.6 4.1 3.0–5.0
Bilirubin, (mg/dL) 0.4 1.2 0.8 0.9 0.4 0.4 0.5 0.6 < 1.1
Prothrombin time, (%) 70 73 68 70 82 83 91 86 70–100
Patient 1: 44-year-old Caucasian female with AL-lambda amyloidosis; patient 2: 65-year-old Caucasian male with AA amyloidosis and familial
Mediterranean fever; patient 3: 40-year-old African male with AA amyloidosis but without clinical features of chronic inflammatory disease;
patient 4: 70-years-old Caucasian male, with hereditary ApoAI-amyloidosis
Table 2
Immunological markers of patients studied
Patient 1 Patient 2 Patient 3 Patient 4 Normal values
ANA negative negative negative negative negative
AMA negative negative negative negative negative
ANCA (screen) negative negative negative negative negative
IgG (g/dL) 0.85 1.32 1.07 1.48 0.8–1.8
IgA (mg/dL) 0.22 0.35 0.29 0.31 0.1–0.45
IgM (mg/dL) 0.01 0.12 0.20 0.19 0.06–0.26
Patient 1: 44-year-old Caucasian female with AL-lambda amyloidosis; patient 2: 65-year-old Caucasian male with AA amyloidosis and familial
Mediterranean fever; patient 3: 40-year-old African male with AA amyloidosis but without clinical features of chronic inflammatory disease.
Patient 4: 70-years-old Caucasian male, with hereditary ApoAI-amyloidosis. ANA – antinuclar antibodies; AMA – antimitochondrial antibiodies;
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Liver biopsies of all four patients revealed amyloid deposits
which were positive to Congo red staining (Figure 1). Fur-
ther molecular characterization of the type of amyloidosis
showed that the patient 4 suffered from hereditary ApoAI-
amyloidosis, a rare disorder characterized by a mutation in
the gene for apolipoprotein AI 
9.
Fig. 1 – Liver biopsy of patient 3. The other two patients
exhibited identical findings. In the vicinity of a portal tract,
extensive extracellular amyloid deposits are seen in all sinu-
soids (arrow), with concomitant finding of atrophic
hepatocytes (Congo red staining, magnification 400).
Prior to the initiation of the treatment, informed consent
was obtained from each patient and the study protocol (con-
forming to the ethical guidelines of the 1975 Declaration of
Helsinki) was approved by the Ethics Committee of the Jo-
hann Wolfgang Goethe University School of Medicine in
Frankfurt.
Independent from body weight, 750 mg ursodeoxy-
cholic acid per day (Ursofalk
®, Dr Falk Pharma GmbH,
Freiburg, Germany) divided into three daily doses were ad-
ministered to all patients.
After 2 to 4 weeks of treatment, a significant decrease
in serum alkaline phosphatase and gamma-glutamyl transfer-
ase levels in comparison to pretreatment values was observed
in all patients, while other liver function tests remained un-
changed (Figure 2). Patients 1 and 2 also reported a signifi-
cant improvement of their pruritus. There was no change in
the liver size on follow up (ultrasound) and renal function
tests remained unchanged. Four weeks after the treatment
with ursodeoxycholic acid was started the patients were dis-
charged from our outpatients clinic and were treated by their
general practitioners, with regular (1–3 months) follow-up
visits to us. Three of the patients (patients 1–3), however,
interrupted ursodeoxycholic acid treatment only a few weeks
after being discharged, since their family physicians decided,
due to high costs, not to prescribe the drug any longer. In the
patient 4 alkaline phosphatase decreased to normal (100
U/L), and in patients 2 and 4 gamma-glytamyl transferase
fell to one third of the pretreatment values.
The patients 1–3 were seen again in our clinic after ur-
sodeoxycholic acid treatment was discontinued; in all three,
cholestatic parameters again markedly increased (Figure 2).
Reintroducing ursodeoxycholic acid (750 mg per day) again
resulted in a decrease in serum alkaline phosphatase and
gamma-glutamyl transferase levels as early as one week after
the treatment was reintroduced. Again, there was no change
in other liver function tests.
Fig. 2 – Decrease in serum alkaline phosphatase and gamma-
glutamyl transferase during treatment with ursodeoxycholic acid
(UDCA; 750 mg per day) and their reversal after the treatment was
temporarily discontinued. Patient 1: 44-year-old Caucasian female
with AL-lambda amyloidosis; patient 2: 65-year-old Caucasian
male with AA amyloidosis and familial Mediterranean fever; pati-
ent 3: 40-year-old African male with AA amyloidosis but without
clinical features of chronic inflammatory disease; patient 4: 70-
years-old Caucasian male, with hereditary ApoAI-amyloidosis.
(normal range: AP < 180 U/L, γ-GT < 28 U/L).
Ursodeoxycholic acid was well tolerated by all patients.
However, they all refused a repeated liver biopsy aimed to
assess possible histological changes due to ursodeoxycholic
acid treatment. One of the patients (patient 1) died of heart
failure shortly after the treatment with ursodeoxycholic acid
was reinitiated, but the other two maintained stabilised pa-
rameters of cholestasis over time (Figure 2). The patient 2Volumen 66, Broj 6 VOJNOSANITETSKI PREGLED Strana 485
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again interrupted ursodeoxycholic acid therapy after a treat-
ment period of six weeks; alkaline phosphatase and gamma-
glutamyl transferase again increased, and returned to previ-
ous values after the treatment was reintroduced. The patient
4 was taking ursodeoxycholic acid without any interruption
for almost six months, and, on the last follow-up, had nearly
normalized parameters of cholestasis (Figure 2).
Discussion
Here we describe four patients with hepatic amylodosis
and cholestasis, who were successfully treated with ursode-
oxycholic acid and stabilized their laboratory parameters of
cholestasis within weeks after the initiation of therapy. The
effect of ursodeoxycholic acid was specific, since temporary
discontinuation of the drug resulted in a recurrent increase in
alkaline phosphatase and gamma-glutamyl transferase, which
again returned to nearly normal values after ursodeoxycholic
acid was reintroduced. Among our four patients, however,
one patient died during the course of treatment due to heart
failure caused by amyloidosis of the heart.
A relatively small series of patients with liver amyloi-
dosis available for this study at present does not allow any
conclusion whether treatment with ursodeoxycholic acid can
influence survival. If any analogy between the two chole-
static diseases can be helpful, in patients with primary biliary
cirrhosis it has been shown that ursodeoxycholic acid delays
the need for transplantation, while the posttransplantation
outcome of ursodeoxycholic acid-treated patients is not dif-
ferent from those who were administered placebo 
10, 11.
Chronic cholestatic liver diseases are characterized by
impaired bile flow, caused by different mechanisms and cell
structures, like the bile salt dependent and independent bile
flow, different export pumps, ATP, glutathione and the cyto-
skeleton 
12–14. Amyloidosis with liver involvement is rela-
tively rare in comparison to amyloidotic disease of the kid-
neys, lung and heart, is characterized by the accumulation of
amyloid fibrilis in the liver parenchyma and ultimately may
result in chronic intrahepatic cholestasis 
15. Amyloid is de-
posited in the parenchyma and in the wall of blood vessels in
the liver, as well as around the bile canaliculi.
Experimental evidence suggests that, in principle, ur-
sodeoxycholic acid acts at least on two major levels in re-
lieving cholestasis in man: it protects cholangiocytes
against cytotoxic effects of hydrophobic bile acids and bile
acid–induced apoptosis, and it stimulates hepatobiliary se-
cretion 
16. On cellular level, ursodeoxycholic acid stimu-
lates ATP secretion in the liver, mobilizes intracellular cal-
cium and activates phospholipase A, induces a pleiotropic
metabolic response in the hepatocyte by activating protein
kinase C, inserts bile acid transporters in the apical pole of
the hepatocyte canalicular membrane, and stabilizes the
hepatocyte membranes and liver mitochondria 
17–23. In pa-
tients with biliary liver diseases it has also been suggested
that ursodeoxycholic acid acts primarily within the bile ca-
nalicular lumen, by preventing disruption of the plasma
membrane of bile duct epithelial cells by hydrophobic bile
acids 
24. Whether one or all of these mechanisms lie be-
neath the described anti-cholestatic effect of ursodeoxy-
cholic acid in patients with severe liver amyloidosis, still
remains to be seen.
Conclusion
Our data imply that ursodeoxycholic acid should be
used to treat cholestasis in patients with liver amyloidosis.
Further clinical studies at a larger patient group are obvi-
ously needed to assess this promising conclusion.
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